10.17.11
Oragenics, Inc., Tampa, FL, has been issued patent No. 8,034,571 from the U.S. Patent and Trademark office for In Vivo Induced Antigen Technology (IVIAT). This platform technology is a novel approach for studying microbial pathogenesis that identifies genes of a pathogenic organism, which are differentially expressed during an actual human infection. IVIAT can be applied to all pathogenic bacteria, yeasts and parasites to rapidly identify proteins that are expressed when a pathogen infects a human. Such proteins are excellent targets for medical diagnostics and therapeutic strategies.